<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00817999</url>
  </required_header>
  <id_info>
    <org_study_id>08-15073</org_study_id>
    <nct_id>NCT00817999</nct_id>
  </id_info>
  <brief_title>The Impact of Grapefruit Juice on the Response to Clopidogrel</brief_title>
  <official_title>The Impact of Grapefruit Juice on the Response to a Loading Dose and Maintenance Dose of Clopidogrel in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Creighton University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Creighton University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will measure the percentage of platelet aggregation inhibition with a loading dose
      of clopidogrel (300 mg) using the VerifyNow Assay System in healthy volunteers who have drank
      11 oz of grapefruit juice. It will also measure the percentage of platelet aggregation
      inhibition with a maintenance dose of clopidogrel (75 mg/day) using the VerifyNow Assay
      System in healthy volunteers who have drank 11 oz grapefruit juice daily.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will examine the effect of GFJ on the loading dose (300 mg) of clopidogrel and
      will evaluate the effect of GFJ on the maintenance dose (75 mg/day) of clopidogrel. Subjects
      will be randomized to either initially receive GFJ prior to their loading dose of clopidogrel
      or receive GFJ prior to their second loading dose. The subjects who have been randomized to
      receive GFJ initially will drink two small cans (11 oz total) of regular strength GFJ in the
      morning, followed two hours later by a loading dose (300 mg) of clopidogrel and will then
      return to the clinic 6 hours after their loading dose to have their platelet inhibition
      measured. Subjects will have ~ 5 milliliters (1 teaspoonful) of whole blood drawn from an
      antecubital vein in their forearm via a 21 gauge needle attached to a blue-top plastic
      vacuette sodium citrate blood collection (Greiner, Monroe, NC) tube to test inhibition of
      platelet aggregation. After their first loading dose, a 2 week washout period will follow to
      allow for their platelet aggregation to return to normal. Following the washout period, the
      subjects will take their second loading dose of clopidogrel and again return to the clinic
      for platelet inhibition measurement. The same timing will be followed for the loading dose
      taken without prior GFJ.

      During the maintenance dose phase of this study, subjects will take 75 mg/day clopidogrel for
      7 days with or without GFJ. Subjects will be randomized to either GFJ during the first period
      or GFJ during the second period. A minimum 2 week washout period will occur between the two 7
      day courses of clopidogrel. Platelet inhibition measurement will occur at the end of each 7
      day period as described above.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>% Platelet Inhibition</measure>
    <time_frame>6 hours</time_frame>
    <description>% platelet inhibition measured by Verify Now</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Loading Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a 300 mg dose of clopidogrel with or without GFJ.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintenance Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received clopidogrel 75 mg/day for 7 days with or without GFJ</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Grapefruit juice</intervention_name>
    <description>Participants received grapefruit juice during 1 of the 2 periods.</description>
    <arm_group_label>Loading Dose</arm_group_label>
    <arm_group_label>Maintenance Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel 75 mg/day</intervention_name>
    <arm_group_label>Maintenance Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel 300 mg</intervention_name>
    <arm_group_label>Loading Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 19-40

          -  Health status confirmed by medical history and physical examination and laboratory
             analysis

        Exclusion Criteria:

          -  Pregnancy

          -  Taking routine prescription or over-the-counter prescriptions

          -  Taken over-the-counter analgesic/anti-inflammatory medication within two weeks of
             study participation

          -  Recently had grapefruit juice or regularly drinks grapefruit juice
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tammy Burns, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Creighton Cardiac Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Creighton Cardiac Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2009</study_first_submitted>
  <study_first_submitted_qc>January 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2009</study_first_posted>
  <results_first_submitted>August 8, 2011</results_first_submitted>
  <results_first_submitted_qc>August 28, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 1, 2012</results_first_posted>
  <last_update_submitted>August 28, 2012</last_update_submitted>
  <last_update_submitted_qc>August 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Platelet Aggregation Inhibition</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Loading Dose</title>
          <description>Healthy volunteers who received a 300 mg dose of clopidogrel with or without grapefruit juice.</description>
        </group>
        <group group_id="P2">
          <title>Maintenance Dose</title>
          <description>Healthy volunteers who received clopidogrel 75 mg/day for 7 days during each period with or without grapefruit juice.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Grapefruit Juice</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>No Grapefruit Juice</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Loading Dose</title>
        </group>
        <group group_id="B2">
          <title>Maintenance Dose</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.4" spread="5.9"/>
                    <measurement group_id="B2" value="25.47" spread="5.66"/>
                    <measurement group_id="B3" value="25.47" spread="5.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>% Platelet Inhibition</title>
        <description>% platelet inhibition measured by Verify Now</description>
        <time_frame>6 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Loading Dose With Grapefruit Juice</title>
          </group>
          <group group_id="O2">
            <title>Maintenance Dose With Grapefruit Juice</title>
          </group>
          <group group_id="O3">
            <title>Loading Dose Without Grapefruit Juice</title>
          </group>
          <group group_id="O4">
            <title>Maintenance Dose Without Grapefruit Juice</title>
          </group>
        </group_list>
        <measure>
          <title>% Platelet Inhibition</title>
          <description>% platelet inhibition measured by Verify Now</description>
          <units>percentage of platelet inhibition</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.4" spread="14.2"/>
                    <measurement group_id="O2" value="24.6" spread="24.2"/>
                    <measurement group_id="O3" value="41.2" spread="19.1"/>
                    <measurement group_id="O4" value="59" spread="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Loading Dose</title>
        </group>
        <group group_id="E2">
          <title>Maintenance Dose</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tammy Burns, PharmD</name_or_title>
      <organization>Creighton University</organization>
      <phone>402-280-4292</phone>
      <email>TammyBurns@creighton.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

